-
-
Overview
-
Antigen Distribution: Hepsin is expressed on the surface of epithelial cells including the liver, kidney, prostate, and thyroid in human tissues.
Specificity: Clone 3H10.1.2 is able to recognize full-length native Hepsin expressed on the cell surface in addition to the recombinant soluble form. Clones 3H1.1.1 and 1F2.1.1 bind to the same epitope as clone 3H10.1.2 and inhibit it (and each other) from binding Hepsin. Clone 3H10.1.2 and clone 2D5.1.9 bind separate epitopes and do not inhibit each other from binding Hepsin.
Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Isotype Control: Mouse IgG1 Isotype Control for In Vivo - Low Endotoxin [HKSP] (ICH2247)
Endotoxin: ≤ 0.75 EU/mg as determined by the LAL method
Aggregation: Aggregation level ≤ 1%Please contact us at for specific academic pricing.
Background
Hepsin is a type II transmembrane serine protease (TTSP) expressed on the surface of epithelial cells including the liver, kidney, prostate, and thyroid in human tissues. The physiological function of hepsin is unclear, although, In vitro studies have shown that hepsin activates blood clotting factors VII, XII, and IX, pro-urokinase (pro-uPA), and pro-hepatocyte growth factor (pro-HGF). The over-expression of hepsin has been implicated in several types of cancer, especially ovarian and prostate, which makes it an attractive diagnostic marker for cancers. Most notably, hepsin has been identified as one of the most highly induced genes in prostate cancer, and this over-expression is correlated with the cancer progression and metastasis. Furthermore anti-hepsin antibodies have been shown to inhibit the invasion of human prostate cancer cells.6
-
- Properties
- Applications
-
Overview